166 related articles for article (PubMed ID: 33635593)
1. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
3. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
4. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
[TBL] [Abstract][Full Text] [Related]
6. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
8. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
9. [Post chemoterapy febrile neutropenia. Length of stay and experience in our population].
Pérez-Heras Í; Raynero-Mellado RC; Díaz-Merchán R; Domínguez-Pinilla N
An Pediatr (Engl Ed); 2020 Mar; 92(3):141-146. PubMed ID: 31239190
[TBL] [Abstract][Full Text] [Related]
10. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
12. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
13. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
[TBL] [Abstract][Full Text] [Related]
14. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia.
Tew M; Forster D; Teh BW; Dalziel K
Aust Health Rev; 2019 Oct; 43(5):549-555. PubMed ID: 31526466
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.
Schelenz S; Giles D; Abdallah S
Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152
[TBL] [Abstract][Full Text] [Related]
16. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP
Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002
[TBL] [Abstract][Full Text] [Related]
17. Emergency Ambulatory Management of Low-Risk Febrile Neutropenia: Multinational Association for Supportive Care in Cancer Fits-Real-World Experience From a UK Cancer Center.
Marshall W; Campbell G; Knight T; Al-Sayed T; Cooksley T
J Emerg Med; 2020 Mar; 58(3):444-448. PubMed ID: 31744709
[TBL] [Abstract][Full Text] [Related]
18. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
[TBL] [Abstract][Full Text] [Related]
19. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
20. [Initial management of febrile neutropenia].
Badertscher L; Damak H; Mercier L; Décosterd D
Rev Med Suisse; 2016 Aug; 12(526):1321-1325. PubMed ID: 28671776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
